menu search

INRLF / Valneva: VLA1553 Takes The Lead In The Chikungunya Vaccine Race

Valneva: VLA1553 Takes The Lead In The Chikungunya Vaccine Race
Positive Phase 3 data from Bavarian Nordic's chikungunya virus (CHIKV) vaccine candidate, PXVX0317, reinforces bullish view on Valneva's VLA1553 due to its superior clinical profile. Valneva's VLA1553 demonstrated impressive seroresponse rates and durability, with future data releases from Bavarian Nordic's additional Phase 3 trial expected to provide a comprehensive comparison between the two vaccines. Valneva has submitted a regulatory application to Health Canada for VLA1553 approval and received Fast Track. Read More
Posted: Jul 18 2023, 04:17
Author Name: Seeking Alpha
Views: 112523

INRLF News  

Valneva's Vaccination Valor: A Buy Rating Justified

By Seeking Alpha
October 4, 2023

Valneva's Vaccination Valor: A Buy Rating Justified

Valneva's 1H 2023 revenue declined compared to the previous year, but product sales more than doubled, driven by the recovery in the travel market. Th more_horizontal

Pfizer, Valneva announce 'positive' results for Lyme disease vaccine candidate booster shot

By Reuters
September 7, 2023

Pfizer, Valneva announce 'positive' results for Lyme disease vaccine candidate booster shot

Pfizer and French pharmaceutical peer Valneva announced on Thursday that a phase 2 study for its VLA15 Lyme disease vaccine candidate showed a "strong more_horizontal

Valneva: VLA1553 Takes The Lead In The Chikungunya Vaccine Race

By Seeking Alpha
July 18, 2023

Valneva: VLA1553 Takes The Lead In The Chikungunya Vaccine Race

Positive Phase 3 data from Bavarian Nordic's chikungunya virus (CHIKV) vaccine candidate, PXVX0317, reinforces bullish view on Valneva's VLA1553 due t more_horizontal


Search within

Pages Search Results: